JOURNAL ARTICLE

Hongkui Deng.

  • Published In: Time.com, 2025. P. N.PAG 1 of 3

  • Database: Academic Search Ultimate 2 of 3

  • Authored By: Hu, Charlotte 3 of 3

Abstract

The article focuses on Hongkui Deng’s pioneering human diabetes trial that uses a novel stem cell reprogramming technique to enable patients to produce their own insulin. Deng, a professor of cell biology at Peking University, adapted a method originally developed by Nobel laureate Shinya Yamanaka to chemically reprogram a patient’s extracted fat cells into insulin-producing cells without genetic engineering. Early results from the trial show that patients with type 1 diabetes have become insulin-independent, with one patient maintaining normal blood sugar levels for nearly two years. This approach represents a potential functional cure for diabetes and may be extended to treat other conditions such as liver failure.

Additional Information

  • Source:Time.com. 2025/05, pN.PAG
  • Document Type:Article
  • Subject Area:Business and Management
  • Publication Date:2025
  • ISSN:2476-2679
  • Accession Number:185035029
  • Copyright Statement:Copyright of Time.com is the property of TIME USA, LLC and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.